Skip to main content
Cash
Portfolio
Log in
Sign up
Trending
Midterms
Elections
Politics
Sports
Culture
Crypto
Commodities
Climate
Economics
Mentions
Finance
Tech & Science
Predict
Live
158
Account
Search
Social
MARKETS
INVEST
LIVE
158
PRO
MORE
Medtronic (MDT) earnings | Kalshi
Medtronic
MDT
Q2 Earnings Call
Reports
Nov 24, 2026 · before open
Fiscal period
Q2 2027
Market cap
$129.95B
Consensus EPS
$1.34 · 8 estimates
Year-ago EPS
$1.36
Expected change
-1.5%
Quarterly markets
What will Medtronic say during their next earnings call?
Trade
MiniMed
94%
Headwind
93%
Sphere-9
92%
Tariff
92%
Tailwind
82%
China
51%
PulseSelect
49%
Security / Cybersecurity
14%
Simplera
12%
GLP-1
8%
Abbott
7%
Q2 Cardiovascular Organic Revenue Growth
Open interest
3,062
Volume
7.8K
Trade
Other figures MDT reports
29 more reported metrics with no market on them yet
Acute Care & Monitoring Revenue
Cardiac Rhythm & Heart Failure Revenue
Cardiovascular Operating Profit
Cardiovascular Revenue
CardioVascular Surgery Revenue
Coronary & Peripheral Vascular Revenue
Cranial & Spinal Technologies Revenue
Diabetes Operating Profit
Diabetes Organic Revenue Growth
Diabetes Revenue
Emerging Markets Revenue
Interventional Cardiology Therapies Revenue
Medical Surgical Operating Profit
Medical Surgical Organic Revenue Growth
Medical Surgical Revenue
Neuromodulation Revenue
Neuroscience Operating Profit
Neuroscience Organic Revenue Growth
Neuroscience Revenue
Non-U.S. Developed Markets Revenue
Other Segment Operating Profit
Other Segment Revenue
Peripheral Vascular Health Revenue
Specialty Therapies Revenue
Structural Heart & Aortic Revenue
Surgical & Endoscopy Revenue
Total International Revenue
Total Organic Revenue Growth
U.S. Revenue
Acute Care & Monitoring Revenue
Cardiac Rhythm & Heart Failure Revenue
Cardiovascular Operating Profit
Cardiovascular Revenue
CardioVascular Surgery Revenue
Coronary & Peripheral Vascular Revenue
Cranial & Spinal Technologies Revenue
Diabetes Operating Profit
Diabetes Organic Revenue Growth
Diabetes Revenue
Emerging Markets Revenue
Interventional Cardiology Therapies Revenue
Medical Surgical Operating Profit
Medical Surgical Organic Revenue Growth
Medical Surgical Revenue
Neuromodulation Revenue
Neuroscience Operating Profit
Neuroscience Organic Revenue Growth
Neuroscience Revenue
Non-U.S. Developed Markets Revenue
Other Segment Operating Profit
Other Segment Revenue
Peripheral Vascular Health Revenue
Specialty Therapies Revenue
Structural Heart & Aortic Revenue
Surgical & Endoscopy Revenue
Total International Revenue
Total Organic Revenue Growth
U.S. Revenue
Q1 2027 reported
$539,000,000
-5.1% QoQ
No market on this figure
Q2 forecast from Kalshi traders
11.26%
-40.4% QoQ
Reported
Market implied
Q1 2027 reported
$539,000,000
-5.1% QoQ
Reported